MX2020007526A - Composiciones y metodos para tratar el cancer. - Google Patents
Composiciones y metodos para tratar el cancer.Info
- Publication number
- MX2020007526A MX2020007526A MX2020007526A MX2020007526A MX2020007526A MX 2020007526 A MX2020007526 A MX 2020007526A MX 2020007526 A MX2020007526 A MX 2020007526A MX 2020007526 A MX2020007526 A MX 2020007526A MX 2020007526 A MX2020007526 A MX 2020007526A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating cancer
- compositions
- tert
- butylpyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620209P | 2018-01-22 | 2018-01-22 | |
| PCT/US2019/014489 WO2019144098A1 (en) | 2018-01-22 | 2019-01-22 | Compositions and methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007526A true MX2020007526A (es) | 2020-09-09 |
Family
ID=65279826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007526A MX2020007526A (es) | 2018-01-22 | 2019-01-22 | Composiciones y metodos para tratar el cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190224205A1 (enExample) |
| EP (1) | EP3743076A1 (enExample) |
| JP (1) | JP2021511344A (enExample) |
| KR (1) | KR20200112904A (enExample) |
| CN (1) | CN111629731A (enExample) |
| AU (1) | AU2019209435A1 (enExample) |
| BR (1) | BR112020014574A2 (enExample) |
| CA (1) | CA3088542A1 (enExample) |
| EA (1) | EA202091751A1 (enExample) |
| IL (1) | IL276203A (enExample) |
| MX (1) | MX2020007526A (enExample) |
| SG (1) | SG11202006823XA (enExample) |
| WO (1) | WO2019144098A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2726206C2 (ru) | 2015-05-21 | 2020-07-09 | Кемосентрикс, Инк. | Модуляторы ccr2 |
| EP3687525B1 (en) | 2017-09-25 | 2025-10-29 | ChemoCentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| CN102484041B (zh) * | 2009-08-21 | 2015-09-23 | 第一太阳能有限公司 | 高温计 |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| RU2766890C2 (ru) * | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| EP3389581A2 (en) * | 2015-12-15 | 2018-10-24 | The Procter and Gamble Company | Leg gasketing cuff with tackifier-free adhesive |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| SMT202200088T1 (it) * | 2017-07-20 | 2022-03-21 | Bristol Myers Squibb Co | Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide |
-
2019
- 2019-01-22 SG SG11202006823XA patent/SG11202006823XA/en unknown
- 2019-01-22 KR KR1020207023850A patent/KR20200112904A/ko not_active Withdrawn
- 2019-01-22 CA CA3088542A patent/CA3088542A1/en active Pending
- 2019-01-22 AU AU2019209435A patent/AU2019209435A1/en not_active Abandoned
- 2019-01-22 EP EP19703615.5A patent/EP3743076A1/en not_active Withdrawn
- 2019-01-22 EA EA202091751A patent/EA202091751A1/ru unknown
- 2019-01-22 JP JP2020540459A patent/JP2021511344A/ja active Pending
- 2019-01-22 WO PCT/US2019/014489 patent/WO2019144098A1/en not_active Ceased
- 2019-01-22 US US16/253,353 patent/US20190224205A1/en not_active Abandoned
- 2019-01-22 MX MX2020007526A patent/MX2020007526A/es unknown
- 2019-01-22 CN CN201980009423.0A patent/CN111629731A/zh active Pending
- 2019-01-22 BR BR112020014574-2A patent/BR112020014574A2/pt not_active IP Right Cessation
-
2020
- 2020-07-21 IL IL276203A patent/IL276203A/en unknown
-
2022
- 2022-01-21 US US17/581,481 patent/US20220160718A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202006823XA (en) | 2020-08-28 |
| CN111629731A (zh) | 2020-09-04 |
| US20220160718A1 (en) | 2022-05-26 |
| US20190224205A1 (en) | 2019-07-25 |
| JP2021511344A (ja) | 2021-05-06 |
| BR112020014574A2 (pt) | 2020-12-08 |
| EP3743076A1 (en) | 2020-12-02 |
| EA202091751A1 (ru) | 2020-11-06 |
| WO2019144098A1 (en) | 2019-07-25 |
| KR20200112904A (ko) | 2020-10-05 |
| AU2019209435A1 (en) | 2020-09-17 |
| IL276203A (en) | 2020-09-30 |
| CA3088542A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220163A1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| PH12021550020A1 (en) | High-affinity, isoform-selective tgf#1 inhibitors and use thereof | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| EA202091751A1 (ru) | Композиции и способы лечения рака | |
| MA44612B1 (fr) | Méthodes de traitement de cancers pédiatriques | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| EA201792522A1 (ru) | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 | |
| NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
| EP4389142A3 (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| EA201990548A1 (ru) | Лечение кластерной головной боли | |
| EA200970923A1 (ru) | АНТИ-EpСАМ АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ | |
| CL2021002656A1 (es) | Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso. | |
| EA201892541A1 (ru) | Гуманизированные анти-il-1r3 антитела | |
| PH12021552903A1 (en) | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof | |
| EP4219556A3 (en) | Human monoclonal antibodies specific for flt3 and uses thereof | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
| MX2021011181A (es) | Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos. | |
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| MX2023010567A (es) | Variantes de anticuerpos no activadoras. | |
| WO2019028182A3 (en) | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) | |
| EA202090563A1 (ru) | Анти-pacap антитело | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. |